CONNECTA Therapeutics raises €3.1 million led by Clave Capital for fragile X trial

The story so far, in brief; the legwork, and the full article, stay with the original outlet.

CONNECTA Therapeutics, a clinical-stage biotech developing drugs that modulate neuroplasticity in central nervous system disorders, has closed a €3.1 million round. Clave Capital led it through its Innvierte Science Tech Clave Innohealth fund. Everyone else at the table already owned a piece of the company: Inveready, CDTI Innvierte and the Prous Institute for Biomedical Research. Inveready, a backer since the seed stage, came in this time through BIO Fund IV. Ignacio Prieto Fernández, an investment associate at Clave, joins the board.

The money is for CTH120, the company's lead candidate for fragile X syndrome, a rare neurodevelopmental disorder that has no specific treatment today. After preclinical work and Phase I safety data, a Phase IIa trial started in June 2026 with 30 randomised adult men. It runs at the Hospital del Mar Research Institute and the Parc Taulí research and innovation institute, and the Centre for Genomic Regulation is helping look for biomarkers. The Ministry of Science, Innovation and Universities and the EU's NextGenerationEU programme already fund the study itself. The new round is meant to see it to completion, and preliminary results are expected around mid-2027. A paediatric programme is being prepared under the FRAXCURE project, which the European Innovation Council co-funds.

Co-founder and chief executive Jordi Fàbrega called the financing "a significant milestone" for the company. So the state is paying to run the trial, mostly familiar shareholders are paying to finish it, and the answer arrives in 2027.